Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009

Winner of LA's Best Award 2009

Los Angeles dentist, Dr. Sam Muslin, DDS, MAGD, has been awarded LA's Best Award (tm) 2009 for his leading edge, high quality dentistry.

16 Sep 2009

Understanding Mexico's management of the A(H1N1) outbreak

When the hitherto undetected A(H1N1) influenza attacked Mexico explosively in late April 2009, the world watched with critical attention as that country's leaders scrambled to manage the emerging public health crisis.

16 Sep 2009

Free caregivers provided to veterans and their spouses by TheraCare

Now, free long term care services, both home and community based, are being offered to qualified veterans and their spouses by TheraCare Home Health and Staffing, LLC.

16 Sep 2009

MDVIP's medical director suggests preventive measures for flu

Dr. Bernard Kaminetsky, the medical director of MDVIP, a national network of affiliated primary care doctors focused on preventive care, recommends, “Talk to your primary care physician now about the flu, both seasonal and H1N1 flu. Your primary care doctor is the one who can best prepare you for the upcoming season with vaccinations as well as information specific to you.”

16 Sep 2009

Pros and cons of HIV treatments in developing countries

Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP).

16 Sep 2009

FDA approves sBLA for Influenza A (H1N1) 2009 Monovalent Vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.

16 Sep 2009

Phase III EXTEND trial results of pixantrone announced

Cell Therapeutics, Inc. (CTI) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.

16 Sep 2009

BioMedReports.Com issues special investigative report on CEL-SCI

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special investigative report on CEL-SCI Corporation.

16 Sep 2009

Clinical trial data of Lipsovir presented at ICAAC

Medivir presented Lipsovir (ME-609) at a poster session on 14th September at the ongoing ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meeting.

16 Sep 2009

Laser technology lowers manufacturing cost of artificial joints and arterial stents

Researchers are developing technologies that use lasers to create arterial stents and longer-lasting medical implants that could be manufactured 10 times faster and also less expensively than is now possible.

16 Sep 2009

Urgent vaccine requirements for treating epidemic diseases voiced at ECI 2009

As a result of dominant media coverage of new epidemic threats such as swine influenza, other infection risks receive less public attention than they deserve. "We would like to bring to everybody's attention that the infectious diseases with the most severe consequences continue to be old acquaintances such as tuberculosis, HIV/AIDS, malaria and hepatitis C. About six million people worldwide die of these diseases every year," says Professor Dr. Dr. h. c. Stefan H. E. Kaufmann, Director of the Max Planck Institute for Infection Biology in Berlin, at the 2nd European Congress of Immunology ECI 2009.

16 Sep 2009

CIDRAP summit to address employee protection measures during H1N1 pandemic

Business and healthcare leaders looking to fast-track preparedness for the H1N1 pandemic are gathering with infectious disease experts and Fortune 500 planners this month to determine how best to protect their employees and preserve their operations.

16 Sep 2009

Also in Global Health News: PNG, Nepal outbreaks; Taliban Oks polio vaccination; Technology helps in developing countries; Satellite images for malaria control

VOA News examines the ongoing struggle for Papua New Guinea's health system to treat thousands of people infected by the "simultaneous outbreaks of influenza, dysentery and cholera that have killed about 120 people." The article includes information about the difficulties heath officials are having in assessing the various outbreaks and concerns of medical workers that conditions may soon worsen (Mercer, 9/14).

16 Sep 2009

WHO says 3b people worldwide could receive H1N1 vaccine

Recent findings that a single dose of an H1N1 (swine) flu vaccine offers protection against the virus and anticipation of vaccination programs starting earlier than predicted will increase the number of people worldwide with access to the vaccine and the likelihood health officials may be able to control the spread of the virus, Bloomberg reports.

16 Sep 2009

Four H1N1 vaccines approved by FDA

The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

16 Sep 2009

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection.

16 Sep 2009

Members of BCBSF to receive coverage for the administration of the H1N1 vaccine

Blue Cross and Blue Shield of Florida, Inc. (BCBSF) announces today its plans to offer coverage for the administration of the H1N1 vaccine to all members when it becomes commercially available to the public. The vaccine administration will be covered for members whose health care plans cover vaccines, as well as for those members whose plans currently do not include immunizations.

15 Sep 2009

American Lung Association urges families to get immunized against seasonal influenza

The American Lung Association is intensifying its seasonal influenza public education initiative to urge families to get vaccinated as soon as possible. The Faces of Influenza campaign aims to ensure Americans get immunized against seasonal influenza, which each year causes an estimated 36,000 deaths and over 226,000 hospitalizations from the virus and its related complications.

15 Sep 2009

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.

15 Sep 2009